{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:34:28Z","timestamp":1790174068728,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s12325-012-0037-5","type":"journal-article","created":{"date-parts":[[2012,8,10]],"date-time":"2012-08-10T12:18:35Z","timestamp":1344601115000},"page":"664-674","source":"Crossref","is-referenced-by-count":80,"title":["Treatment Patterns in the First Year After Initiating Tumor Necrosis Factor Blockers in Real-World Settings"],"prefix":"10.1007","volume":"29","author":[{"given":"Machaon","family":"Bonafede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Princic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shravanthi R.","family":"Gandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,8]]},"reference":[{"key":"37_CR1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2474-9-52","volume":"9","author":"A. Alonso-Ruiz","year":"2008","unstructured":"Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord. 2008;9:52.","journal-title":"BMC Musculoskelet Disord"},{"key":"37_CR2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.7326\/0003-4819-148-2-200801150-00192","volume":"148","author":"K.E. Donahue","year":"2008","unstructured":"Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008;148:124\u2013134.","journal-title":"Ann Intern Med"},{"key":"37_CR3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/03009740701607067","volume":"36","author":"L.E. Kristensen","year":"2007","unstructured":"Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsoe B, Saxne T. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand J Rheumatol. 2007;36:411\u2013417.","journal-title":"Scand J Rheumatol"},{"key":"37_CR4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1503\/cmaj.091391","volume":"181","author":"J.A. Singh","year":"2009","unstructured":"Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ. 2009;181:787\u2013796.","journal-title":"CMAJ"},{"key":"37_CR5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000233234","volume":"219","author":"N. Bansback","year":"2009","unstructured":"Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009;219:209\u2013218.","journal-title":"Dermatology"},{"key":"37_CR6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2133.2008.08732.x","volume":"159","author":"J. Schmitt","year":"2008","unstructured":"Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderateto-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159:513\u2013526.","journal-title":"Br J Dermatol"},{"key":"37_CR7","first-page":"883","volume":"35","author":"A.A. Saad","year":"2008","unstructured":"Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2008;35:883\u2013890.","journal-title":"J Rheumatol"},{"key":"37_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11280","volume":"11","author":"C. McLeod","year":"2007","unstructured":"McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1\u2013158, iii\u2013iv.","journal-title":"Health Technol Assess"},{"key":"37_CR9","first-page":"107","volume":"61","author":"R. Scrivo","year":"2009","unstructured":"Scrivo R, Conti F, Spinelli FR, et al. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo. 2009;61:107\u2013117.","journal-title":"Reumatismo"},{"key":"37_CR10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","volume":"56","author":"K.L. Hyrich","year":"2007","unstructured":"Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one antitumor necrosis factor alpha agent to a second antitumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56:13\u201320.","journal-title":"Arthritis Rheum"},{"key":"37_CR11","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1471-2474-12-204","volume":"12","author":"S. Ogale","year":"2011","unstructured":"Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord. 2011;12:204.","journal-title":"BMC Musculoskelet Disord"},{"key":"37_CR12","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar2084","volume":"8","author":"L.E. Kristensen","year":"2006","unstructured":"Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther. 2006;8:R174.","journal-title":"Arthritis Res Ther"},{"key":"37_CR13","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1136\/ard.2007.083675","volume":"67","author":"W. Kievit","year":"2008","unstructured":"Kievit W, Adang EM, Fransen J, et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis. 2008;67:1229\u20131234.","journal-title":"Ann Rheum Dis"},{"key":"37_CR14","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.24463","volume":"61","author":"S.M. Pan Du","year":"2009","unstructured":"Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009;61:560\u2013568.","journal-title":"Arthritis Rheum"},{"key":"37_CR15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1749-6632.2009.04621.x","volume":"1173","author":"A. Marchesoni","year":"2009","unstructured":"Marchesoni A, Zaccara E, Gorla R, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173:837\u2013846.","journal-title":"Ann N Y Acad Sci"},{"key":"37_CR16","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1136\/ard.2008.098467","volume":"68","author":"A. Strangfeld","year":"2009","unstructured":"Strangfeld A, Hierse F, Kekow J, et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis. 2009;68:1856\u20131862.","journal-title":"Ann Rheum Dis"},{"key":"37_CR17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"M.L. Hetland","year":"2010","unstructured":"Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62:22\u201332.","journal-title":"Arthritis Rheum"},{"key":"37_CR18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/annrheumdis-2011-200302","volume":"71","author":"J.J. Gomez-Reino","year":"2012","unstructured":"Gomez-Reino JJ, Rodriguez-Lozano C, Campos-Fernandez C, Montoro M, Descalzo MA, Carmona L. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis. 2012;71:382\u2013385.","journal-title":"Ann Rheum Dis"},{"key":"37_CR19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","volume":"59","author":"M.S. Heiberg","year":"2008","unstructured":"Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of antitumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59:234\u2013240.","journal-title":"Arthritis Rheum"},{"key":"37_CR20","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar1941","volume":"8","author":"L. Carmona","year":"2006","unstructured":"Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther. 2006;8:R72.","journal-title":"Arthritis Res Ther"},{"key":"37_CR21","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"K.G. Saag","year":"2008","unstructured":"Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762\u2013784.","journal-title":"Arthritis Rheum"},{"key":"37_CR22","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A. Menter","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826\u2013850.","journal-title":"J Am Acad Dermatol"},{"key":"37_CR23","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","volume":"58","author":"A. Gottlieb","year":"2008","unstructured":"Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851\u2013864.","journal-title":"J Am Acad Dermatol"},{"key":"37_CR24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","volume":"62","author":"J. Braun","year":"2003","unstructured":"Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2003;62:817\u2013824.","journal-title":"Ann Rheum Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s12325-012-0037-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T22:42:17Z","timestamp":1497998537000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-012-0037-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["37"],"URL":"https:\/\/doi.org\/10.1007\/s12325-012-0037-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}